Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer (NCT03659448)
Multicenter, Open-label, Randomized, Controlled, Parallel Arms Clinical Study on Performance of SGM-101, a Fluorochrome-labeled Anti-CEA Monoclonal Antibody, for Delineation of Primary/Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer
🩺 Plain-English Summary (8th-Grade Level)
The performance of SGM-101, an intraoperative imaging agent, will be compared to that of standard "white light" visualization during surgical resections of colorectal cancer.
Who can join: Review the eligibility criteria below.
Location: City of Hope National Medical Center — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (11 Sites)
- City of Hope National Medical Center — Duarte, California
- Moores Cancer Center - UCSD Health — La Jolla, California
- Cleveland Clinic Florida — Weston, Florida
- Massachusetts General Hospital — Boston, Massachusetts
- University of Massachusetts — Worcester, Massachusetts
- Perelman Center for Advanced Medicine — Philadelphia, Pennsylvania
- Universitätsmedizin Göttingen, Klinik für Allgemein- Viszeral- und Kinderchirurgie — Göttingen,
- Fondazione IRCCS Policlinico San Matteo — Pavia, Lombardy
- Catharina Ziekenhuis Eindhoven — Eindhoven,
- Leiden University Medical Center — Leiden,
- Erasmus MC — Rotterdam,
📞 Contact the Study Coordinator
Phone: (812) 325-7657
Email: johna.warner@outlook.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Colorectal Neoplasms
- S0820, Adenoma and Second Primary Prevention Trial — Birmingham, Alabama
- MyGI Diet for Colorectal Cancer Prevention — Ann Arbor, Michigan
- A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer — Gilbert, Arizona
- Combination Immunotherapy in Colorectal Cancer — Brooklyn, New York
- Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors — Encinitas, California
- Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can... — Bethesda, Maryland
Explore by condition: All Colorectal Neoplasms clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.